Making drugs is tricky business. It’s also expensive, so it’s no shocker that labs take scientific shortcuts when trying to get a treatment to market—where it can start earning back the millions of dollars spent in development. Whenever the FDA catches falsified data or unreported side effects, it issues a warning letter to document the bad research. That’s good. But a new study shows the FDA also goes to extreme lengths—from bureaucratic obfuscation to outright redaction...
Read more: http://ift.tt/1FMR3Oc
No comments:
Post a Comment